Bio-Path Statistics
Share Statistics
Bio-Path has 4.31M shares outstanding. The number of shares has increased by -77.73% in one year.
| Shares Outstanding | 4.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 22.69% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.31M |
| Failed to Deliver (FTD) Shares | 1.52K |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 77.76K, so 1.81% of the outstanding shares have been sold short.
| Short Interest | 77.76K |
| Short % of Shares Out | 1.81% |
| Short % of Float | 1.81% |
| Short Ratio (days to cover) | 0.03 |
Valuation Ratios
The PE ratio is -0.28 and the forward PE ratio is -0.22.
| PE Ratio | -0.28 |
| Forward PE | -0.22 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 10.04 |
| P/FCF Ratio | -0.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Bio-Path Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.6, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.6 |
| Quick Ratio | 1.6 |
| Debt / Equity | 0.23 |
| Total Debt / Capitalization | 18.93 |
| Cash Flow / Debt | -111.99 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -36.46% and return on capital (ROIC) is -2859.75%.
| Return on Equity (ROE) | -36.46% |
| Return on Assets (ROA) | -4.99% |
| Return on Capital (ROIC) | -2859.75% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.61M |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -92.98% in the last 52 weeks. The beta is 0.22, so Bio-Path 's price volatility has been higher than the market average.
| Beta | 0.22 |
| 52-Week Price Change | -92.98% |
| 50-Day Moving Average | 0.9 |
| 200-Day Moving Average | 2.05 |
| Relative Strength Index (RSI) | 36.95 |
| Average Volume (20 Days) | 1.20M |
Income Statement
In the last 12 months, Bio-Path had revenue of $0 and earned -$16.08M in profits. Earnings per share was $-33.64.
| Revenue | 0 |
| Gross Profit | -178.00K |
| Operating Income | -15.84M |
| Net Income | -16.08M |
| EBITDA | -15.76M |
| EBIT | - |
| Earnings Per Share (EPS) | -33.64 |
Balance Sheet
The company has $1.05M in cash and $113.00K in debt, giving a net cash position of $939.00K.
| Cash & Cash Equivalents | 1.05M |
| Total Debt | 113.00K |
| Net Cash | 939.00K |
| Retained Earnings | -107.61M |
| Total Assets | 2.96M |
| Working Capital | -476.00K |
Cash Flow
In the last 12 months, operating cash flow was -$11.54M and capital expenditures $0, giving a free cash flow of -$11.54M.
| Operating Cash Flow | -11.54M |
| Capital Expenditures | 0 |
| Free Cash Flow | -11.54M |
| FCF Per Share | -24.13 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BPTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5096.97% |
| FCF Yield | -405.06% |
Analyst Forecast
The average price target for BPTH is $20, which is 2930.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 2930.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Feb 23, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Feb 23, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -67.59 |
| Piotroski F-Score | 2 |